Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage Not for the Faint of CAR-T

The CAR-T Therapy Landscape in 2015

EP Vantage Pharma & Biotech Preview 2015

Download EP Vantage Not for the Faint of CAR-T: The CAR-T Therapy Landscape in 2015

The market interest surrounding anti-tumour CAR-T therapies was one of the defining themes of 2014 and investor enthusiasm for the area is unlikely to abate in 2015. But there may be hidden dangers for those seeking to make big returns, according to a new report published by EP Vantage, based on market intelligence from EvaluatePharma.


The Bio Report Podcast: Should Investors Temper Their Enthusiasm for CAR-T Therapies with Jacob Plieth, Senior Reporter at EP Vantage.

Key highlights in EP Vantage's CAR-T Therapy Landscape in 2015:

  • The most promising candidates in development
  • The most clinically advanced products
  • A detailed look at the largely ignored risks of CAR-T therapy
  • Strategies to increase safety
  • Intellectual property issues
  • Beyond CAR-T - the next generation of products
  • Smaller companies to watch

Download EP Vantage CAR-T Therapy Landscape in 2015

Press Release

Related Reports: 

EP Vantage Pharma & Biotech 2015 Preview

EvaluatePharma Orphan Drug Report 2014

EvaluatePharma World Preview 2014, Outlook to 2020